BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant


4/24/2009 11:06:48 AM

Grant Supports First Blood Test for Depression

SAN DIEGO, April 23 /PRNewswire/ -- Ridge Diagnostics, Inc., a neurodiagnostic company commercializing its first-in-class, proprietary blood test for depression or Major Depressive Disorder(MDD), has been awarded a Phase 2, National Science Foundation, Small Business Innovation Research (SBIR) Program grant. The grant will be used to further the clinical development and commercialization of its blood test for depression, the first blood test for any neuropsychiatric disorder.

In January 2009, the company completed the commercial launch of its CLIA certified laboratory in Research Triangle Park, NC. The laboratory provides testing information to physicians, pharmaceutical companies and clinical research organizations. The test can be used in pharmaceutical research to objectively identify and stratify patient populations to enhance drug research and clinical studies. It is intended to be used by psychiatrists and primary care physicians to diagnose and monitor treatment of patients with depression. A biological test based upon the physiological changes caused by depression could drive the earlier diagnosis, and treatment management of the over 20 million adults in the U.S. facing this disease.

"We are pleased to once again, announce the National Science Foundation's recognition of Ridge's technological accomplishments. This prestigious grant will enable us to further the clinical development of our blood tests and build on our CLIA laboratory infrastructure to support our growing business," stated Stan Sewitch, President and CEO of Ridge.

Ridge Diagnostics, Inc. is a neurodiagnostic company commercializing a breakthrough, first-in-class, proprietary blood test for the diagnosis and treatment monitoring of Major Depressive Disorder (MDD). The company's products are derived from a proprietary Human Biomarker Library and Hyper-Mapping(TM) technology. Ridge intends to develop a comprehensive neuropsychiatric disease diagnostic franchise. Ridge Diagnostics testing services are provided through its CLIA certified laboratory in North Carolina, then through diagnostic test kits sold worldwide. The company is located in San Diego, CA and Research Triangle Park, NC.

CONTACT: Lonna J Williams, CCO of Ridge Diagnostics, Inc., 1-877-743-4301

Web site: http://www.ridgedx.com/



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->